Literature DB >> 16855807

Improved long-term survival after liver resection for hepatocellular carcinoma in the modern era: retrospective study from HCV-endemic areas.

Atsushi Sasaki1, Yukio Iwashita, Kohei Shibata, Toshifumi Matsumoto, Masayuki Ohta, Seigo Kitano.   

Abstract

INTRODUCTION: It remains unclear whether recent progress in perioperative management and treatment for recurrent hepatocellular carcinoma (HCC) has improved patient outcomes in hepatitis C virus-endemic areas.
METHODS: The clinicopathologic and follow-up data of 218 consecutive HCC patients who underwent curative resection between 1982 and 2003 were analyzed. Patients were assigned to one of two groups: before 1992 (early group; n=82) and 1992 and later (late group; n=136). Factors influencing survival rates were investigated by multivariate analysis. The effects of the period during which the hepatic resection was done on the patients' outcome were examined with respect to tumor size.
RESULTS: The 5-year cancer-related and disease-free survival rates were 51.4% and 20.4%, respectively. The late group showed better 5-year cancer-related survival than the early group (64.1% vs. 33.8%), but disease-free survival did not differ significantly between the groups. On multivariate analysis, the period of the hepatic resection was identified as an independent prognostic factor for cancer-related survival (relative risk 0.70, P<0.01) but not disease-free survival. There were no differences in the cancer-related and disease-free survival rates between the two groups for patients with tumors<or=25 mm. In patients with HCCs>50 mm, both cancer-related and disease-free survival rates were better in patients in the late group.
CONCLUSIONS: During the past two decades, improvements in the treatment of recurrent HCC tumors have contributed to controlling large HCCs but not to controlling the multicentric development of HCCs. It may be important to control multicentric recurrence of HCC to improve patient survival in areas where the hepatitis C virus is endemic.

Entities:  

Mesh:

Year:  2006        PMID: 16855807     DOI: 10.1007/s00268-005-0249-9

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  36 in total

1.  Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan.

Authors:  S Arii; Y Yamaoka; S Futagawa; K Inoue; K Kobayashi; M Kojiro; M Makuuchi; Y Nakamura; K Okita; R Yamada
Journal:  Hepatology       Date:  2000-12       Impact factor: 17.425

2.  Clinical management of recurrent hepatocellular carcinoma.

Authors:  P H Lee; W J Lin; Y M Tsang; R H Hu; J C Sheu; M Y Lai; H C Hsu; W May; C S Lee
Journal:  Ann Surg       Date:  1995-11       Impact factor: 12.969

3.  Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma.

Authors:  S Kubo; K Hirohashi; H Tanaka; T Tsukamoto; T Shuto; T Ikebe; T Yamamoto; K Wakasa; S Nishiguchi; T Kuroki; H Kinoshita
Journal:  World J Surg       Date:  2000-12       Impact factor: 3.352

4.  Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value.

Authors:  G L Grazi; G Ercolani; F Pierangeli; M Del Gaudio; M Cescon; A Cavallari; A Mazziotti
Journal:  Ann Surg       Date:  2001-07       Impact factor: 12.969

5.  Postoperative adjuvant arterial infusion chemotherapy for patients with hepatocellular carcinoma.

Authors:  K Nakashima; S Kitano; Y I Kim; M Aramaki; K Kawano
Journal:  Hepatogastroenterology       Date:  1996 Nov-Dec

6.  Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy. Result of multivariate analysis.

Authors:  S Ko; Y Nakajima; H Kanehiro; M Hisanaga; Y Aomatsu; T Kin; K Yagura; T Ohyama; K Nishio; K Ohashi; M Sho; T Yamada; H Nakano
Journal:  Ann Surg       Date:  1996-11       Impact factor: 12.969

7.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.

Authors:  K Ikeda; S Saitoh; I Koida; Y Arase; A Tsubota; K Chayama; H Kumada; M Kawanishi
Journal:  Hepatology       Date:  1993-07       Impact factor: 17.425

8.  Operative results in 143 patients with hepatocellular carcinoma.

Authors:  T Segawa; R Tsuchiya; J Furui; K Izawa; T Tsunoda; T Kanematsu
Journal:  World J Surg       Date:  1993 Sep-Oct       Impact factor: 3.352

9.  Hepatic resection for hepatocellular carcinoma. An audit of 343 patients.

Authors:  E C Lai; S T Fan; C M Lo; K M Chu; C L Liu; J Wong
Journal:  Ann Surg       Date:  1995-03       Impact factor: 12.969

Review 10.  Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future.

Authors:  W Y Lau; Thomas W T Leung; Simon C H Yu; Stephen K W Ho
Journal:  Ann Surg       Date:  2003-02       Impact factor: 12.969

View more
  9 in total

Review 1.  Survival after anatomic resection versus nonanatomic resection for hepatocellular carcinoma: a meta-analysis.

Authors:  Jinggui Chen; Kai Huang; Jianghong Wu; Huiyan Zhu; Yingqiang Shi; Yanong Wang; Guangfa Zhao
Journal:  Dig Dis Sci       Date:  2010-11-17       Impact factor: 3.199

2.  Surgical treatment for early hepatocellular carcinoma: comparison of resection and liver transplantation.

Authors:  Jian Zhou; Zheng Wang; Shuang-Jian Qiu; Xiao-Wu Huang; Jian Sun; Wen Gu; Jia Fan
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-11       Impact factor: 4.553

3.  Post-hepatectomy haemorrhage: a single-centre experience.

Authors:  Aijun Li; Bin Wu; Weiping Zhou; Weifeng Yu; Li Li; Hang Yuan; Mengchao Wu
Journal:  HPB (Oxford)       Date:  2014-07-09       Impact factor: 3.647

4.  Metabolic restaging of hepatocellular carcinoma using whole-body F-FDG PET/CT.

Authors:  Long Sun; Yong-Song Guan; Wei-Min Pan; Zuo-Ming Luo; Ji-Hong Wei; Long Zhao; Hua Wu
Journal:  World J Hepatol       Date:  2009-10-31

5.  Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma.

Authors:  Eli Sapir; Yebin Tao; Matthew J Schipper; Latifa Bazzi; Paula M Novelli; Pauline Devlin; Dawn Owen; Kyle C Cuneo; Theodore S Lawrence; Neehar D Parikh; Mary Feng
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-09-14       Impact factor: 7.038

Review 6.  Management of "very early" hepatocellular carcinoma on cirrhotic patients.

Authors:  Gonzalo Sapisochin; Elena Fernandez de Sevilla; Juan Echeverri; Ramón Charco
Journal:  World J Hepatol       Date:  2014-11-27

7.  Improvement of long-term outcomes in hepatitis C virus antibody-positive patients with hepatocellular carcinoma after hepatectomy in the modern era.

Authors:  Ken Shirabe; Kazuki Takeishi; Akinobu Taketomi; Hideaki Uchiyama; Hiroto Kayashima; Yoshihiko Maehara
Journal:  World J Surg       Date:  2011-05       Impact factor: 3.352

8.  Hepatocellular carcinoma in cirrhotic patients with portal hypertension: is liver resection always contraindicated?

Authors:  Andrea Ruzzenente; Alessandro Valdegamberi; Tommaso Campagnaro; Simone Conci; Silvia Pachera; Calogero Iacono; Alfredo Guglielmi
Journal:  World J Gastroenterol       Date:  2011-12-14       Impact factor: 5.742

9.  Single-step multimodal locoregional treatment for unresectable hepatocellular carcinoma: balloon-occluded percutaneous radiofrequency thermal ablation (BO-RFA) plus transcatheter arterial chemoembolization (TACE).

Authors:  R Iezzi; V Cesario; L Siciliani; M Campanale; A M De Gaetano; M Siciliano; S Agnes; F Giuliante; A Grieco; M Pompili; G L Rapaccini; A Gasbarrini; L Bonomo
Journal:  Radiol Med       Date:  2013-01-28       Impact factor: 3.469

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.